When: Confirmed close >$132.20 with MACD histogram contracting + volume >12M

Then: Add 1% position

When: Q3 earnings catalyst resolution

Then: Add 1% position

WAIT: Do not buy at current levels ($129.48). Wait for either (1) confirmed reversal above $132.20 with positive momentum, or (2) successful test of 200 SMA at $124.86 with positive reversal signals. If using tranche framework, first tranche should be at the level with highest probability of holding, not at current vulnerable level.

• Current price at $129.48 sits $0.80 above lower Bollinger band at $128.68, which is explicitly flagged as a 'high-information level' with $4 billion in buybacks ongoing simultaneously
• MACD histogram expanding into negative territory, MACD line below signal line, 10 EMA crossed below 50 SMA: textbook momentum deterioration requiring waiting for confirmation
• Q1 2026 LT debt issuance was $24.9 billion, Q2 2026 was $59.6 billion: more than doubling of debt issuance in single quarter while leverage ticks from 12.25x to 13.50x
• Q3 earnings consensus for double-digit growth elevates expectations; miss or soft guide on ACL builds could gap stock 5-10 percent lower
• Banamex IPO described as 'still market chatter' with Mexico macro and political risk attached; IPO timing notoriously slip-prone
• Token Services revenue contribution to $24.77 billion quarterly revenue base characterized as 'rounding-error'
• Forward EPS of $12.91 must deliver AND multiple must expand to reach $165-$175 target: base case closer to flat-to-modestly-positive; bear case of multiple compression plus EPS miss gets to $115-$120
• Risk-reward characterized as closer to 1-to-1 than 7-to-1; aggressive PEG mean reversion target requires simultaneous earnings delivery and multiple expansion in credit cycle
• Tranche structure proposed: 1 percent now at $130, 1 percent on 50 SMA reclaim with rising volume, 1 percent on 200 SMA test or ahead of Q3 earnings; problem is tranche-1 at $130 is worst entry in structure
• ATR at $3.20 with recent single-day ranges of $5-$6 means stock can easily sweep below $124 stop intraday before reversing; more conservative stop at $127.50 recommended
• Studies on breakout versus mean-reversion systems show mean-reversion buyer who waits for confirmation captures most of move while early buyer gets stopped out more often
• Sentiment report flagged absence of retail cross-check; institutional sources are only ones telling bullish story and 'can flip fast'

→ vs aggressive: 200 SMA intact 'value zone' framing conflates long-term trend with entry timing; $129.48 is one bad session away from support test, not a low-risk entry

→ vs aggressive: RSI at 39 with mean reversion argument ignores that MACD shows momentum still deteriorating; deploying capital against deteriorating momentum is not disciplined risk management

→ vs aggressive: $59.6 billion LT debt issuance dismissed as 'normal' is actually more than doubling versus Q1 ($24.9B) in single quarter while doing $4B buybacks: pattern that precedes credit-quality deterioration

→ vs aggressive: Catalyst calendar (Q3 earnings, Banamex IPO, Token Services) presents binary risks as confirmed tailwinds; all could disappoint in macro environment of rising rates and ACL building

→ vs aggressive: 7-to-1 risk-reward target of $165-$175 requires simultaneous forward EPS delivery ($12.91) AND multiple expansion in credit cycle; actual base case closer to flat-to-modestly-positive

→ vs aggressive: Tranche-1 entry at $130 contradicts tranche framework logic; highest-probability tranche-1 should be at confirmed bounce, not at most vulnerable level of structure

→ vs aggressive: $124 stop not 'clean invalidation' given ATR of $3.20 and recent $5-$6 single-day ranges; will get stopped out at exactly level where structural bounce most likely

Reduced initial exposure (0.5% tranche one), tightened confirmation requirements for tranche two, catalyst-driven tranche three, $124 stop loss, 2.5% maximum position cap, mid-October review trigger

• Reduce tranche one from 1% to 0.5% due to 50 SMA break, expanding negative MACD, and only $0.80 buffer above lower Bollinger band
• Keep tranche two at $132.20 on 50 SMA reclaim but require daily close above $132.20 with rising volume AND contracting MACD histogram
• Restructure tranche three as Q3 earnings catalyst play rather than buying at $124.86 on 200 SMA test
• Stop loss at $124 (structural invalidation below 200 SMA, lower Bollinger band, and long-term trend line) based on ATR of $3.20
• Reduce maximum position sizing from 3% to 2.5%
• Add mid-October explicit review trigger: if $132.20 not reclaimed and MACD still expanding negative, trim position by half
• Aggressive analyst's 7-to-1 risk-reward requires forward EPS of $12.91 AND multiple expansion simultaneously
• Q1 LT debt issuance was $24.9 billion versus $59.6 billion in Q2 — meaningful acceleration, not steady-state
• Recent single-day ranges are $5 to $6, requiring appropriate volatility buffer
• Fundamental case intact: PEG of 0.61, 9% annual share count reduction, accelerating EPS, loaded catalyst calendar

→ vs aggressive: 7-to-1 risk-reward framing is mathematically dishonest — requires forward EPS of $12.91 AND simultaneous multiple expansion, but in a credit cycle with 30-year yields at 2002 highs and ACLs building, multiples compress even when earnings grow

→ vs aggressive: Q1 to Q2 LT debt issuance jump from $24.9 billion to $59.6 billion is not steady-state housekeeping — that's meaningful acceleration coinciding with capital return exceeding net income, not noise

→ vs aggressive: Institutional-only bullish narrative with no retail cross-check is a vulnerability, not a strength — institutional positioning can flip on single bad print; calling seven binary catalysts 'seven distinct positive catalysts' is selection bias

→ vs aggressive: Missing time-based discipline — no mechanism to force reassessment if thesis is not playing out within reasonable timeframe

→ vs conservative: Waiting for RSI sub-30 means buying at $134 to $138 instead of $130, sacrificing 4 to 6 percent of upside on illusory confirmation that momentum traders systematically avoid highest-quality entries

→ vs conservative: $127.50 stop logic is contradictory — mixing frameworks by proposing tighter stop ($127.50) for someone who hasn't entered yet when original ATR-based stop at $124 is appropriate for pre-entry waiting, not post-entry protection

→ vs conservative: Third tranche at $124.86 on 200 SMA test means averaging down into confirmed breakdown if it fails — two tranches underwater makes position a sitting duck for next leg lower